{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:01:06Z","timestamp":1793682066898,"version":"4.5.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related severe adverse toxic effects are rare. Current studies have shown that the polymorphisms of methylenetetrahydrofolate reductase (<jats:italic>MTHFR<\/jats:italic>) gene can decrease the MTX clearance, leading to the metabolite accumulation. However, there is a lack of literature report on an <jats:italic>MTHFR<\/jats:italic> gene polymorphism associated with adverse toxic effects resulting from the use of LD-MTX in an EP.<\/jats:p><jats:p><jats:bold>Case Presentation:<\/jats:bold> We report a rare case of a 38-year-old female who developed persistent fever, grade IV myelosuppression, skin lesions, mucositis, and liver injury after single dose of LDMTX to treat EP. The personalized genetic testing showed that <jats:italic>MTHFR<\/jats:italic> TT (677C&amp;gt;T) and <jats:italic>MTHFR<\/jats:italic> AA (1298A&amp;gt;C) were detected. Gradually, the symptoms improved after calcium leucovorin (CF) rescue, continuous renal replacement therapy (CRRT), promoting blood system regeneration, and multiple supportive treatments.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This is the first report on the serious adverse toxic effects of LD-MTX on an EP patient with <jats:italic>MTHFR<\/jats:italic> mutations. We aim to alert obstetricians and gynecologists to this rare condition. The unexpected life-threatening toxicity with LD-MTX should be highly considered and recognized early. In particular, some easily overlooked gastrointestinal, skin, and mucosal symptoms occur earlier than severe myelosuppression. When toxic effects are suspected, detecting the polymorphisms of an <jats:italic>MTHFR<\/jats:italic> gene and monitoring MTX concentration in blood could assist us to formulate individualized and active treatments.<\/jats:p>","DOI":"10.3389\/fmed.2021.738315","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:58:56Z","timestamp":1637215136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report"],"prefix":"10.3389","volume":"8","author":[{"given":"Huan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/abr.abr_5_20","article-title":"Which protocol is better for treatment of ectopic pregnancy by methotrexate? Single-dose or multiple-dose","volume":"9","author":"Khani","year":"2020","journal-title":"Adv Biomed Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0015-0282(16)46349-1","article-title":"Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case","volume":"37","author":"Tanaka","year":"1982","journal-title":"Fertil Steril."},{"key":"B3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.fertnstert.2013.06.013","article-title":"Medical treatment of ectopic pregnancy: a committee opinion","volume":"100","year":"2013","journal-title":"Fertil Steril"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1111\/1471-0528.14189","article-title":"Diagnosis and management of ectopic pregnancy","volume":"123","author":"Elson","year":"2016","journal-title":"BJOG."},{"key":"B5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/ced.12062","article-title":"Systemic methotrexate therapy for psoriasis: past, present and future","volume":"38","author":"Dogra","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"13030\/qt46k975h8","DOI":"10.5070\/D3207023133","article-title":"Cutaneous erosions: a herald for impending pancytopenia in methotrexate toxicity","volume":"20","author":"Shiver","year":"2014","journal-title":"Dermatol Online J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jaad.2015.06.015","article-title":"Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker","volume":"73","author":"Delyon","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jcpt.13050","article-title":"Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations","volume":"45","author":"Tan","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4274\/tjod.80457","article-title":"Severe methotrexate toxicity after treatment for ectopic pregnancy: a case report","volume":"13","author":"Soysal","year":"2016","journal-title":"J Turkish Soc Obstetr Gynecol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00228-013-1608-3","article-title":"Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy","volume":"70","author":"Willner","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ajog.2016.06.040","article-title":"Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes","volume":"215","author":"Mergenthal","year":"2016","journal-title":"Am J Obstet Gynecol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejogrb.2016.11.016","article-title":"Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: a comparative study of 400 cases","volume":"208","author":"Bonin","year":"2017","journal-title":"Eur J Obstet Gyn R B."},{"key":"B13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.fertnstert.2006.06.054","article-title":"Use of \u201c2-dose\u201d regimen of methotrexate to treat ectopic pregnancy","volume":"87","author":"Barnhart","year":"2007","journal-title":"Fertil Steril."},{"key":"B14","doi-asserted-by":"publisher","first-page":"107815522095189","DOI":"10.1177\/1078155220951898","article-title":"Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia","volume":"2020","author":"Frikha","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/10245332.2018.1500750","article-title":"The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis","volume":"24","author":"Yao","year":"2019","journal-title":"Hematology (Luxembourg)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.080576","article-title":"Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity","volume":"36","author":"Fisher","year":"2009","journal-title":"J Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1078155208093931","article-title":"Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism","volume":"14","author":"Gammon","year":"2008","journal-title":"J Oncol Pharm Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/humupd\/dmn012","article-title":"Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis","volume":"14","author":"Mol","year":"2008","journal-title":"Hum Reprod Update."},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40199-020-00379-0","article-title":"Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction","volume":"29","author":"Shafie","year":"2021","journal-title":"DARU J Pharmaceut Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5114\/aoms.2016.58844","article-title":"Methotrexate-induced pancytopenia in a patient with ectopic pregnancy","volume":"14","author":"Shao","year":"2018","journal-title":"Arch Med Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.therap.2015.12.006","article-title":"Fatal methotrexate toxicity in a patient treated for an ectopic pregnancy","volume":"71","author":"Ga\u00efes","year":"2016","journal-title":"Therapie."},{"key":"B22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/01.AOG.0000172374.72125.3e","article-title":"A cautionary tale fatal outcome of methotrexate therapy given for management of ectopic pregnancy","volume":"107","author":"Kelly","year":"2006","journal-title":"Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/0029-7844(96)00252-9","article-title":"Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: a report of two cases","volume":"88","author":"Isaacs","year":"1996","journal-title":"Obstetr Gynecol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"bcr0320126023","DOI":"10.1136\/bcr-03-2012-6023","article-title":"Life-threatening complications following multidose methotrexate for medical management of ectopic pregnancy","volume":"2012","author":"Dasari","year":"2012","journal-title":"Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist."},{"key":"B26","doi-asserted-by":"publisher","first-page":"bcr2014203530","DOI":"10.1136\/bcr-2014-203530","article-title":"The utility of online haemodiafiltration in methotrexate poisoning","volume":"2014","author":"Abdelsalam","year":"2014","journal-title":"Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1089\/gtmb.2017.0124","article-title":"MTRR A66G,RFC1 G80A, and MTHFR C677T and A1298C polymorphisms and disease activity in mexicans with rheumatoid arthritis treated with methotrexate","volume":"21","author":"Gonz\u00e1lez-Mercado","year":"2017","journal-title":"Genet Test Mol Bioma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","article-title":"Methotrexate: clinical pharmacology, current status and therapeutic guidelines","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3109\/s10165-007-0582-y","article-title":"Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients","volume":"17","author":"Shoda","year":"2007","journal-title":"Mod Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.738315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:58:58Z","timestamp":1637215138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.738315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":29,"alternative-id":["10.3389\/fmed.2021.738315"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.738315","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"738315"}}